MedTrace Logo

Total Cerebral Protection With Embolic Protection Devices Thoracic Aortic Stenting

NCT04062539 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2019-08-22

No results posted yet for this study

Summary

Stroke and silent cerebral infarction are a real risk with thoracic enodvascular aortic repair (TEVAR). The investigator propose to prospectively observational study with enrolment of all patients undergoing TEVAR for thoracic and thoracoabdominal conditions including aneurysmal degeneration, Type B dissection and acute aortic syndromes over a 24 month period, equating to a minimum of 20-30 patients per year. Patients undergoing juxtra-renal and infra-renal aortic stenting will form a control group.

Conditions

  • Stroke
  • Silent Cerebral Infarct

Interventions

DEVICE

Sentinel and Spider

Dual filter and single filter

Sponsors & Collaborators

  • St Mary's Hospital, London

    collaborator OTHER

  • Imperial College London

    lead OTHER

Principal Investigators

  • Richard Gibbs · Imperial College London

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-04
Primary Completion
2021-06-30
Completion
2021-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04062539 on ClinicalTrials.gov